Prana Biotechnology (PRAN)
Prana Biotechnology Market Cap: 44.05M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PRAN Market Cap Rankings
| Overall | 13th percentile | 4052 of 4664 |
| Sector | 17th percentile | 436 of 527 in Healthcare |
| Industry | 14th percentile | 140 of 164 in Biotechnology |
PRAN Market Cap Range, Past 5 Years
| Minimum | 24.32M | Jun 2009 |
| Maximum | 79.90M | Mar 2008 |
| Average | 44.84M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these PRAN related companies
PRAN News
Prana Enrolls First Patient in the "Reach2HD" Phase II Huntington Disease Trial
Apr 30, 8:57AM Marketwire
Apr 30, 8:57AM Marketwire
PLoS ONE Journal Publishes Mechanistic Model of Alzheimer's Disease Endorsing Prana's PBT2
Mar 26, 8:30AM Marketwire
Mar 26, 8:30AM Marketwire
Prana Doses First Patient in the "IMAGINE" Phase II Alzheimer's Disease Trial
Mar 07, 8:30AM Benzinga
Mar 07, 8:30AM Benzinga
$pran is climbing Mount Everest. Jump on everyone that follow me. Also $chtp $glng $cldx. Hurry!
about 115 days ago by JohnVan
about 115 days ago by JohnVan
FDA Approval to Commence Huntington's Disease Clinical Trial Using Prana's PBT2
Jan 04, 10:53AM Marketwire
Jan 04, 10:53AM Marketwire
$PRAN shares trending higher this AM, now up 12.6% amid PR from co. confirming FDA approval for Alz. trial; news first heard last night
about 191 days ago by Street_Insider
about 191 days ago by Street_Insider
Prana Biotechnology (PRAN) Receives Approval by Austin Health Research Ethics Committee for Alzheimer's Trial
Nov 22, 9:06AM Street Insider
Nov 22, 9:06AM Street Insider
Australian Federal Government Funds Study Into Neuroprotective Benefits of Prana's PBT2
Oct 27, 10:00AM Marketwire
Oct 27, 10:00AM Marketwire
Australian Federal Government Grant to Study Effect of PBT2 in the Ageing Brain
Oct 20, 8:30AM Marketwire
Oct 20, 8:30AM Marketwire
Prana (PRAN) Reports Publication of Positive Data for PBT2 on Restoring Cognitive Function in Alzheimer's Patients
Sep 19, 9:24AM Street Insider
Sep 19, 9:24AM Street Insider
Prana's Planned Huntington's Trial Receives Strong Interest From Patients and Researchers
Sep 15, 10:42AM Benzinga
Sep 15, 10:42AM Benzinga
Prana receives Michael J. Fox Foundation grant to develop PBT434 for Parkinson's
Aug 22, 9:01AM FlyOnTheWall
Aug 22, 9:01AM FlyOnTheWall
$PRAN may run through $2.00 on sympathy http://stk.ly/p2sRd3
about 309 days ago by inthemoneytraders
about 309 days ago by inthemoneytraders
$PRAN enters At-The-Market Issuance Sales Agreement w/MLV & from time to time may sell up to 50m ord shs/5m ADRs http://1.usa.gov/qD9jZY
about 323 days ago by TradeHawk
about 323 days ago by TradeHawk
Got a load on some more $PRAN tomorrow, quick bounce to 2$ this week
about 340 days ago by CashCow66
about 340 days ago by CashCow66
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PRAN | 1.60 | +0.00 | +0.00% | 44.05M |
| PRAA | 68.30 | -0.69 | -1.00% | 1.183B |
| PRA | 87.98 | -0.25 | -0.28% | 2.695B |
| PQ | 4.82 | -0.15 | -3.02% | 318.58M |
| PPT | 5.435 | -0.01 | -0.28% | |
| PPR | 5.54 | +0.00 | +0.00% | |
| PPO | 37.22 | -0.78 | -2.05% | 1.767B |
| PNBC | 0.7131 | -0.09 | -10.86% | 2.375M |
| PMTC | 19.99 | -0.48 | -2.34% | 2.438B |
| PMT | 18.21 | -0.24 | -1.30% | 554.61M |
